Table 2. Association between antiestrogens use and incidence of cervical neoplasia in the breast cancer cohort.

	5 year follow-up						10 year follow-up
	Low-grade dysplasia			High-grade dysplasia			High-grade dysplasia			ICC
	Nonuser	AI-included	Tamoxifen only	Nonuser	AI-included	Tamoxifen only	Nonuser	AI-included	Tamoxifen only	Nonuser	AI-included	Tamoxifen only
No. of patients	15136	7516	19761	15076	7510	19660	14893	8084	19018	14843	8064	18935
Patients with event	113	33	200	53	27	99	63	30	103	13	10	20
Person-years	49154	26953	66633	49095	26942	66415	60919	38091	79764	60780	38025	79610
Incidence per 105person-years	230	122	300	108	100	149	103	79	129	21	26	25
95% CI	191-276	86.8-172	261-344	82-141	68-146	122-181	80-132	55-112	106-156	12-36	14-48	16-38

HR: hazard ratio;

^aModel adjusted for age, Pap smear density and chemotherapy